Launching a Diagnostic Testing Innovator at the Height of COVID-19: Alveo Technologies

When the COVID-19 pandemic accelerated demand for rapid, accessible diagnostic testing, Alveo Technologies faced both an opportunity and an urgent challenge. Originally an at-home diagnostic testing startup, the company rapidly pivoted its development roadmap to support COVID-19 test innovation and move toward regulatory authorization under Emergency Use Authorization (EUA) pathways.

The Challenge

Alveo, an at-home diagnostic testing startup, accelerated its launch timeline in response to the COVID-19 pandemic and pivoted to pursue authorization for a COVID-19 test.

The company needed to quickly introduce its brand, promote major milestones, and build credibility for its novel approach to at-home diagnostics.

The Strategy

Establish Credibility

Announced a strategic partnership with Janssen Pharmaceuticals to introduce the company and validate its technology.

Prepare for Scale

Built a comprehensive PR strategy ahead of anticipated Emergency Use Authorization (EUA) news.

Elevate Leadership

Leveraged social media and thought leadership to position the CEO as a leading voice in at-home diagnostics.

The Result

Alveo rapidly established visibility during a critical moment in the pandemic, earning top-tier media coverage and positioning its CEO as a trusted expert on diagnostic testing.

The campaign also laid the groundwork for a high-impact announcement tied to future regulatory milestones.

The Impact

Interviews Secured With:

The Wall Street Journal
TIME
Forbes
San Francisco Business Times

Featured Coverage

MobiHealthNews
HIT Consultant
Integrated Healthcare Executive
Authority Magazine

Results Like These Start With a Conversation.

Let's talk about what breaking through looks like for your organization.

Let's Talk